PRODUCT INFORMATION



LG 100754

Item No. 19647

CAS Registry No.: 180713-37-5

Formal Name: 3-methyl-7-(5,6,7,8-tetrahydro-

5,5,8,8-tetramethyl-3-propoxy-2-naphthalenyl)- 2E,4E,6Z-

octatrienoic acid


Synonyms: CD3159, LGD 100754, UVI2112

MF: $C_{26}H_{36}O_{3}$ FW: 396.6 **Purity:** ≥98%

 λ_{max} : 246, 256, 318 nm UV/Vis.: A crystalline solid Supplied as:

-20°C Storage: Stability: ≥4 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.



Laboratory Procedures

LG 100754 is supplied as a crystalline solid. A stock solution may be made by dissolving the LG 100754 in the solvent of choice. LG 100754 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of LG 100754 in these solvents is approximately 5, 20, and 30 mg/ml, respectively.

LG 100754 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, LG 100754 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. LG 100754 has a solubility of approximately 0.25 mg/ml in a 1:3 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

LG 100754 is a ligand of retinoid X receptor (RXR) that modulates the activity of RXR dimers. It acts as an antagonist towards RXR homodimers but as an agonist of heterodimers consisting of RXR and retinoic acid receptor (RAR) or PPARs. $^{1-3}$ LG 100754, at 1 μ M, is a weak agonist of RXR-PPAR γ but strongly enhances signaling through the heterodimer in response to PPARy ligands, including rosiglitazone (Item No. 71740) and 15-deoxy- $\Delta^{12,14}$ -prostaglandin J₂ (Item No. 18570). Through this action, LG 100754 decreases glucose levels and relieves insulin resistance in mice.^{4,5}

References

- 1. Hida, T., Tai, K., Tokuhara, N., et al. Existence of retinoic acid-receptor-independent retinoid X-receptordependent pathway in myeloid cell function. Jpn. J. Pharmacol. 85(1), 60-69 (2001).
- Lala, D.S., Mukherjee, R., Schulman, I.G., et al. Activation of specific RXR heterodimers by an antagonist of RXR homodimers. Nature 383(6599), 450-453 (1996).
- Schulman, I.G., Li, C.J., Schwabe, W.R., et al. The phantom ligand effect: Allosteric control of transcription by the retinoid X receptor. Genes Dev. 11(3), 299-308 (1997).
- Forman, B.M. The antidiabetic agent LG100754 sensitizes cells to low concentrations of peroxisome proliferator-activated receptor gamma ligands. J. Biol. Chem. 277(15), 12503-12506 (2002).
- Cesario, R.M., Klausing, K., Razzaghi, H., et al. The rexinoid LG100754 is a novel RXR:PPARy agonist and decreases glucose levels in vivo. Mol. Endocrinol. 15(8), 1360-1369 (2001).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information Buyer agrees to purchase the mater can be found on our website.

Copyright Cayman Chemical Company, 11/02/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM